ストックスクリーナーアプリを入手
169.73
0.23%
0.39
アフターアワーズ：
168.00
-1.73
-1.02%
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca stock steadies as oncology and vaccines underpin earnings momentum - Ad-hoc-news.de
Jefferies says September lung data can offset AstraZeneca trial failure - Proactive financial news
London Deal Activity Keeps Healthcare Stocks In Focus As AstraZeneca (LSE:AZN) Sets The Tone - Kalkine Media
Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance UK
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com Canada
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - The Manila Times
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
AstraZeneca stock trades steady as oncology and cardiovascular portfolio underpin growth - Ad-hoc-news.de
Earnings Preview: AstraZeneca to Report Financial Results on July 27 - 富途牛牛
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula - GuruFocus
AstraZeneca stock trades steady as oncology and vaccines underpin growth - Ad-hoc-news.de
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
AstraZeneca stock holds as earnings and pipeline milestones support valuation - Ad-hoc-news.de
AstraZeneca stock trades steady as oncology revenue supports 2025 outlook - Ad-hoc-news.de
ASTRAZENECA : JP Morgan gives a Buy rating - marketscreener.com
What Is Keeping AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock steadies as oncology growth supports guidance after latest quarterly update - Ad-hoc-news.de
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
AstraZeneca stock trades steadily as oncology and cardiovascular pipeline supports long term growth - Ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Investors to Connect - The National Law Review
AstraZeneca slips Monday, underperforms market - MarketWatch
AstraZeneca stock trades steadily as oncology and rare disease growth underpin earnings - Ad-hoc-news.de
What Is Putting AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock trades around recent highs as oncology growth supports valuation - Ad-hoc-news.de
AstraZeneca highlights rare diseases in $80bn revenue push - Financial Times
AstraZeneca PLC (AZN.L) Investor Outlook: Assessing a 25% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
AstraZeneca stock steady as recent earnings and pipeline progress frame investor debate - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Stockholders to Connect - Stockhouse
AstraZeneca’s Fresh Cancer Drug Boost: What’s Behind the Latest Share Momentum? - Kalkine Media
AstraZeneca stock holds as investors await fresh evidence - ad-hoc-news.de
AstraZeneca stock steady as oncology and rare disease pipeline supports growth - ad-hoc-news.de
Why Is AstraZeneca (LSE:AZN) Drawing Fresh Attention On Oncology Approvals? - Kalkine Media
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AstraZeneca stock holds on to its earnings momentum - ad-hoc-news.de
AstraZeneca stock trades steady as oncology and rare disease pipeline underpins long term growth - ad-hoc-news.de
AstraZeneca stock trades steadily as oncology and rare disease pipeline underpins long term growth - ad-hoc-news.de
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
AstraZeneca stock holds as 2025 revenue and profit stay in focus - Ad Hoc News
AstraZeneca stock edges higher as oncology and cardiovascular growth supports outlook - ad-hoc-news.de
Why Is AstraZeneca (LSE:AZN) Back in Healthcare Focus? - Kalkine Media
Why Is AstraZeneca (LSE:AZN) Leading the Blue-Chip Debate? - Kalkine Media
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AstraZeneca PLC (AZN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume - CryptoSlate
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - PR Newswire
Attractive Growth Profile Positions AstraZeneca PLC (AZN) as an Investment Bet - Yahoo Finance
What AstraZeneca (LSE:AZN) Says About The Mood Around Healthcare Stocks - Kalkine Media
Why Is AstraZeneca (LSE:AZN) Holding Firm Near Record Highs? - Kalkine Media
AZN Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Investors to Inquire about Securities Investigation - ACCESS Newswire
AstraZeneca’s Oncology Engine Keeps Running Despite Wainua Setback (NYSE:AZN) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZ - The National Law Review
AstraZeneca rises Wednesday, outperforms market - MarketWatch
AstraZeneca pays up to $1.5bn for lung cancer drug - BioXconomy
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug - Pharmaceutical Technology
Is AstraZeneca Quietly Rewriting Its Regulatory Story This Week? - Kalkine Media
AstraZeneca slides Tuesday, underperforms market - MarketWatch
Astrazeneca nabs PDE3/4 inhibitor for COPD in $2.1B Sino deal - BioWorld News
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical - Reuters
AstraZeneca To Acquire Lung Cancer Drug License For $1.5B - Law360
AstraZeneca stock holds steady as investors wait for a catalyst - Ad-hoc-news.de
AstraZeneca Secures Licensing Deal for Zegfrovy (AZN) - GuruFocus
AstraZeneca (NASDAQ: AZN) signs global Zegfrovy lung cancer deal - Stock Titan
Is AstraZeneca (LSE:AZN) Worth Watching After Its Latest Regulatory Wins? - Kalkine Media
AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Can - GuruFocus
0.51%
0.96%
大文字化:
|
ボリューム (24 時間):